Research programme: anticancer therapies - Chong Kun Dang

Drug Profile

Research programme: anticancer therapies - Chong Kun Dang

Alternative Names: 3,5-dimethoxy-4-hydroxyethoxycinnamoyl fumagillol; 4-hydroxyethoxycinnamoyl fumagillol; CKD-731

Latest Information Update: 13 May 2010

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class Esters
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 07 Jun 2000 A preclinical study has been added to the Cancer pharmacodynamics section
  • 01 Jun 2000 New profile
  • 01 Jun 2000 Preclinical development for Cancer in South Korea (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top